[{"orgOrder":0,"company":"University of Rochester","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"University of Rochester","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Rochester \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"1","companyTruncated":"University of Rochester \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2015","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Eye-yon Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Eye-yon Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eye-yon Medical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Eye-yon Medical \/ Undisclosed"},{"orgOrder":0,"company":"Eye-yon Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Eye-yon Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eye-yon Medical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Eye-yon Medical \/ Undisclosed"},{"orgOrder":0,"company":"L.V. Prasad Eye Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Oligonucleotide","year":"2010","type":"Inapplicable","leadProduct":"Pegaptanib","moa":"angiogenesis inhibitors; aptamers","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"L.V. Prasad Eye Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"L.V. Prasad Eye Institute \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"L.V. Prasad Eye Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"St. Joseph's Healthcare Hamilton","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2012","type":"Inapplicable","leadProduct":"Zinc","moa":"B1 bradykinin receptor; Methylated-DNA--protein-cysteine methyltransferase; Fructose-bisphosphate aldolase A; Elongation factor 1-alpha 1; Alpha-enolase; Glyceraldehyde-3-phosphate dehydrogenase, testis-specific; Nucleoside diphosphate kinase A; Protein disulfide-isomerase; Protein disulfide-isomerase A3; Peroxiredoxin-1; Phosphoserine phosphatase; Triosephosphate isomerase; Elongation factor Tu, mitochondrial; Estrogen receptor; Interleukin-3; Metallothionein-2; Copper chaperone for superoxide dismutase; Histone deacetylase 1; Histone deacetylase 4; DNA-3-methyladenine glycosylase; Semenogelin-1; Superoxide dismutase [Cu-Zn]; Histone deacetylase 8; Apoptosis regulatory protein Siva; Glycine receptor subunit alpha-1; E3 ubiquitin-protein ligase Mdm2; Insulin; Utrophin; Aspartoacylase; Protein S100-A8; Protein S100-A9; Matrix metalloproteinase-9; Tumor protein p73; Protein S100-A2; Cellular tumor antigen p53; Metallothionein-3; Programmed cell death protein 6; DAN domain family member 5","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"St. Joseph's Healthcare Hamilton","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"St. Joseph's Healthcare Hamilton \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"St. Joseph's Healthcare Hamilton \/ Undisclosed"},{"orgOrder":0,"company":"Southern California College of Optometry at Marshall B. Ketchum University","sponsor":"Alcon Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Propylene Glycol","moa":"B12-independent glycerol dehydratase","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Southern California College of Optometry at Marshall B. Ketchum University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Southern California College of Optometry at Marshall B. Ketchum University \/ Alcon Inc","highestDevelopmentStatusID":"1","companyTruncated":"Southern California College of Optometry at Marshall B. Ketchum University \/ Alcon Inc"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Alcon Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Propylene Glycol","moa":"B12-independent glycerol dehydratase","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Alcon Inc","highestDevelopmentStatusID":"1","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Alcon Inc"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Propylene Glycol","moa":"B12-independent glycerol dehydratase","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Propylene Glycol","moa":"B12-independent glycerol dehydratase","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tetra BioPharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Tetra BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Horama Sa","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2020","type":"Licensing Agreement","leadProduct":"HORA-001","moa":"CRB1","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leiden University Medical Center \/ Horama Sa","highestDevelopmentStatusID":"1","companyTruncated":"Leiden University Medical Center \/ Horama Sa"},{"orgOrder":0,"company":"Melissa Toyos","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Bromfenac","moa":"Cyclooxygenase","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Melissa Toyos","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Melissa Toyos \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"1","companyTruncated":"Melissa Toyos \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"MDbackline, LLC","sponsor":"Alcon Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Nepafenac","moa":"Cyclooxygenase","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"MDbackline, LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"MDbackline, LLC \/ Alcon Inc","highestDevelopmentStatusID":"1","companyTruncated":"MDbackline, LLC \/ Alcon Inc"},{"orgOrder":0,"company":"Intuor Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Nepafenac","moa":"Cyclooxygenase","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Intuor Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Intuor Technologies \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Intuor Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Baylor College of Medicine \/ Allergan","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ Allergan"},{"orgOrder":0,"company":"Eyenovia","sponsor":"SGN Nanopharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eyenovia \/ SGN Nanopharma","highestDevelopmentStatusID":"1","companyTruncated":"Eyenovia \/ SGN Nanopharma"},{"orgOrder":0,"company":"University of Waterloo","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"University of Waterloo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"University of Waterloo \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"1","companyTruncated":"University of Waterloo \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Kedrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Plasminogen","moa":"Fibrinogen","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kedrion \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Kedrion \/ Undisclosed"},{"orgOrder":0,"company":"Retina Research Institute, LLC","sponsor":"Retina-Vitreous Associates Medical Group | West Coast Retina Medical Group, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2013","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Retina Research Institute, LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Retina Research Institute, LLC \/ Retina-Vitreous Associates Medical Group | West Coast Retina Medical Group, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Retina Research Institute, LLC \/ Retina-Vitreous Associates Medical Group | West Coast Retina Medical Group, Inc."},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Unity Health Toronto | Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Sunnybrook Health Sciences Centre \/ Unity Health Toronto | Allergan","highestDevelopmentStatusID":"1","companyTruncated":"Sunnybrook Health Sciences Centre \/ Unity Health Toronto | Allergan"},{"orgOrder":0,"company":"Barnes Retina Institute","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Barnes Retina Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Barnes Retina Institute \/ Allergan","highestDevelopmentStatusID":"1","companyTruncated":"Barnes Retina Institute \/ Allergan"},{"orgOrder":0,"company":"University of Michigan","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2012","type":"Inapplicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"University of Michigan","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Michigan \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"1","companyTruncated":"University of Michigan \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Kala Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Kala Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Kala Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"University of Toronto","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Prednisolone Acetate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Health Toronto \/ University of Toronto","highestDevelopmentStatusID":"1","companyTruncated":"Unity Health Toronto \/ University of Toronto"},{"orgOrder":0,"company":"Irvine School of Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Irvine School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Irvine School of Medicine \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Irvine School of Medicine \/ Undisclosed"},{"orgOrder":0,"company":"University of Miami","sponsor":"Florida Lions Eye Bank","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Plasma Rich In Growth Factors","moa":"Growth factor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Miami \/ Florida Lions Eye Bank","highestDevelopmentStatusID":"1","companyTruncated":"University of Miami \/ Florida Lions Eye Bank"},{"orgOrder":0,"company":"Chung Shan Medical University","sponsor":"Nutrarex Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Chung Shan Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chung Shan Medical University \/ Nutrarex Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Chung Shan Medical University \/ Nutrarex Biotech"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Mantis Photonics","sponsor":"Sundets \u00d6gonl\u00e4kare","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tropicamide","moa":"Muscarinic acetylcholine receptor M3","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Mantis Photonics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mantis Photonics \/ Sundets \u00d6gonl\u00e4kare","highestDevelopmentStatusID":"1","companyTruncated":"Mantis Photonics \/ Sundets \u00d6gonl\u00e4kare"},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"China Medical University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Atropine","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M1","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Kubota Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kubota Pharmaceutical \/ China Medical University Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Kubota Pharmaceutical \/ China Medical University Hospital"},{"orgOrder":0,"company":"VISUfarma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"NETHERLANDS","productType":"Enzyme","year":"2019","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial; Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"VISUfarma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VISUfarma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"VISUfarma \/ Undisclosed"},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"GS010","moa":"ND4 mitochondrial gene","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"GenSight Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenSight Biologics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"GenSight Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ista Tears","moa":"Ocular surface","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Universit\u00e0 degli Studi 'G. d'Annunzio' Chieti e Pescara","sponsor":"OFFHEALTH S.p.A. | Universit\u00e0 degli Studi di Sassari | University of Pisa","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Nicotinamide","moa":"PARP1","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Universit\u00e0 degli Studi 'G. d'Annunzio' Chieti e Pescara","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Universit\u00e0 degli Studi 'G. d'Annunzio' Chieti e Pescara \/ OFFHEALTH S.p.A. | Universit\u00e0 degli Studi di Sassari | University of Pisa","highestDevelopmentStatusID":"1","companyTruncated":"Universit\u00e0 degli Studi 'G. d'Annunzio' Chieti e Pescara \/ OFFHEALTH S.p.A. | Universit\u00e0 degli Studi di Sassari | University of Pisa"},{"orgOrder":0,"company":"Calm Water Therapeutics","sponsor":"Andover Research Eye Institute","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Glycerine","moa":"Peroxisome proliferator-activated receptor delta; Group IIE secretory phospholipase A2; Inositol-3-phosphate synthase 1; All-trans-retinol dehydrogenase [NAD(+)] ADH1B; Inositol 1,4,5-trisphosphate-gated calcium channel ITPR1; Glycodelin; Alpha-N-acetylgalactosaminidase; ADP-ribosylation factor 1; Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 1; DNA mismatch repair protein MutL; Ribonucleoside-diphosphate reductase 1 subunit beta; Adenine DNA glycosylase; tRNA (cytosine(38)-C(5))-methyltransferase; Maleylacetoacetate isomerase","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Calm Water Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calm Water Therapeutics \/ Andover Research Eye Institute","highestDevelopmentStatusID":"1","companyTruncated":"Calm Water Therapeutics \/ Andover Research Eye Institute"},{"orgOrder":0,"company":"Josip Juraj Strossmayer University of Osijek","sponsor":"Plava Medical Group, Bosna and Herzegovina","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CROATIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor alpha; Sterol regulatory element-binding protein 1","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Josip Juraj Strossmayer University of Osijek","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Josip Juraj Strossmayer University of Osijek \/ Plava Medical Group, Bosna and Herzegovina","highestDevelopmentStatusID":"1","companyTruncated":"Josip Juraj Strossmayer University of Osijek \/ Plava Medical Group, Bosna and Herzegovina"},{"orgOrder":0,"company":"Ohio State University","sponsor":"Nordic Naturals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor alpha; Sterol regulatory element-binding protein 1","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Ohio State University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ohio State University \/ Nordic Naturals","highestDevelopmentStatusID":"1","companyTruncated":"Ohio State University \/ Nordic Naturals"},{"orgOrder":0,"company":"Wills Eye Hospital","sponsor":"Physician Recommended Nutriceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor alpha; Sterol regulatory element-binding protein 1","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Wills Eye Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wills Eye Hospital \/ Physician Recommended Nutriceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Wills Eye Hospital \/ Physician Recommended Nutriceuticals"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"Aston University","sponsor":"TearLab Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2015","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Aston University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aston University \/ TearLab Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Aston University \/ TearLab Corporation"},{"orgOrder":0,"company":"Nature's Way Canada","sponsor":"Centre for Contact Lens Research","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Nature's Way Canada","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nature's Way Canada \/ Centre for Contact Lens Research","highestDevelopmentStatusID":"1","companyTruncated":"Nature's Way Canada \/ Centre for Contact Lens Research"},{"orgOrder":0,"company":"Aurolab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"HPAPI","year":"2011","type":"Inapplicable","leadProduct":"Latanoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Aurolab","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aurolab \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Aurolab \/ Undisclosed"},{"orgOrder":0,"company":"Eyenovia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2018","type":"Inapplicable","leadProduct":"Latanoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Eyenovia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eyenovia \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Eyenovia \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2019","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Diego \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"1","companyTruncated":"University of California, San Diego \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Mati Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Travoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Mati Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Insert","sponsorNew":"Mati Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Mati Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"He Eye Hospital","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Diquafosol","moa":"Pyrimidinergic receptor P2Y6 | Pyrimidinergic receptor P2Y4 | Purinergic receptor P2Y1 | Purinergic receptor P2Y2","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"He Eye Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"He Eye Hospital \/ Santen Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"He Eye Hospital \/ Santen Pharmaceutical"},{"orgOrder":0,"company":"EDISON PHARMACEUTICALS INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Vatiquinone","moa":"Quinone reductase 1","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"EDISON PHARMACEUTICALS INC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EDISON PHARMACEUTICALS INC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"EDISON PHARMACEUTICALS INC \/ Undisclosed"},{"orgOrder":0,"company":"Hershey Medical Center","sponsor":"The American Society of Cataract and Refractive Surgery Foundation | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"steroids (androgens","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Hershey Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hershey Medical Center \/ The American Society of Cataract and Refractive Surgery Foundation | GSK","highestDevelopmentStatusID":"1","companyTruncated":"Hershey Medical Center \/ The American Society of Cataract and Refractive Surgery Foundation | GSK"},{"orgOrder":0,"company":"The Norwegian Dry Eye Clinic","sponsor":"Laboratoires Thea","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"NORWAY","productType":"Carbohydrate","year":"2022","type":"Inapplicable","leadProduct":"Trehalose","moa":"TFEB","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"The Norwegian Dry Eye Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Norwegian Dry Eye Clinic \/ Laboratoires Thea","highestDevelopmentStatusID":"1","companyTruncated":"The Norwegian Dry Eye Clinic \/ Laboratoires Thea"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"PharmAbcine","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Partnership","leadProduct":"PMC-403","moa":"Tie2","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ PharmAbcine","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Biologics \/ PharmAbcine"},{"orgOrder":0,"company":"Shanghai BDgene","sponsor":"Beijing Tongren Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BD113 vVLP","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Shanghai BDgene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai BDgene \/ Beijing Tongren Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai BDgene \/ Beijing Tongren Hospital"},{"orgOrder":0,"company":"Glasgow Caledonian University","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"9963X","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Glasgow Caledonian University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Glasgow Caledonian University \/ Allergan","highestDevelopmentStatusID":"1","companyTruncated":"Glasgow Caledonian University \/ Allergan"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Licensing Agreement","leadProduct":"Adeno-associated Virus Vector","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"4D Molecular Therapeutics","amount2":0.95999999999999996,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0.95999999999999996,"dosageForm":"Injection","sponsorNew":"4D Molecular Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"1","companyTruncated":"4D Molecular Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Bioheart","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2013","type":"Inapplicable","leadProduct":"Adipose Derived Stem Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Bioheart","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioheart \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Bioheart \/ Undisclosed"},{"orgOrder":0,"company":"Maisonneuve-Rosemont Hospital","sponsor":"Fonds de recherche en ophtalmologie de l'Universit\u00e9 de Montr\u00e9al | Foundation Fighting Blindness | Retina Foundation of Canada | Insight Instruments | Synergetics Inc | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"AREDS-2","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Maisonneuve-Rosemont Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maisonneuve-Rosemont Hospital \/ Fonds de recherche en ophtalmologie de l'Universit\u00e9 de Montr\u00e9al | Foundation Fighting Blindness | Retina Foundation of Canada | Insight Instruments | Synergetics Inc | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Maisonneuve-Rosemont Hospital \/ Fonds de recherche en ophtalmologie de l'Universit\u00e9 de Montr\u00e9al | Foundation Fighting Blindness | Retina Foundation of Canada | Insight Instruments | Synergetics Inc | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Chung Shan Medical University","sponsor":"Glory Kingdom Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Bilberry","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Chung Shan Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chung Shan Medical University \/ Glory Kingdom Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Chung Shan Medical University \/ Glory Kingdom Corporation"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Black Tomato Extract","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCI Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Zhongshan Ophthalmic Center, Sun Yat-sen University","sponsor":"Blackmores (China) CO., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Carotenoids","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Zhongshan Ophthalmic Center, Sun Yat-sen University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhongshan Ophthalmic Center, Sun Yat-sen University \/ Blackmores (China) CO., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Zhongshan Ophthalmic Center, Sun Yat-sen University \/ Blackmores (China) CO., Ltd"},{"orgOrder":0,"company":"ACRO Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Collagen Ophthalmic Matrix","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"ACRO Biomedical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ACRO Biomedical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"ACRO Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"David Pei-Cheng Lin","sponsor":"Grape King Bio Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Cordyceps Cicadae Mycelia","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"David Pei-Cheng Lin","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"David Pei-Cheng Lin \/ Grape King Bio Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"David Pei-Cheng Lin \/ Grape King Bio Ltd."},{"orgOrder":0,"company":"ZeaVision, LLC","sponsor":"Sound Retina","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"DiVFuSS","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"ZeaVision, LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ZeaVision, LLC \/ Sound Retina","highestDevelopmentStatusID":"1","companyTruncated":"ZeaVision, LLC \/ Sound Retina"},{"orgOrder":0,"company":"Bruder Healthcare","sponsor":"CBCC Global","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Dry Eye Drink","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Bruder Healthcare","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bruder Healthcare \/ CBCC Global","highestDevelopmentStatusID":"1","companyTruncated":"Bruder Healthcare \/ CBCC Global"},{"orgOrder":0,"company":"Bio Nature Health","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Eye Empower","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Bio Nature Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bio Nature Health \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Bio Nature Health \/ Citruslabs"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"FID 114657","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Wills Eye Hospital","sponsor":"Guardian Health Sciences, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Glaucocetin","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Wills Eye Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wills Eye Hospital \/ Guardian Health Sciences, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Wills Eye Hospital \/ Guardian Health Sciences, Inc."},{"orgOrder":0,"company":"Institut de la Macula y la Retina","sponsor":"Igen BioLab SLU","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"IGENH35.3A","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Institut de la Macula y la Retina","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut de la Macula y la Retina \/ Igen BioLab SLU","highestDevelopmentStatusID":"1","companyTruncated":"Institut de la Macula y la Retina \/ Igen BioLab SLU"},{"orgOrder":0,"company":"Lenstatin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Lenstatin","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Lenstatin","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lenstatin \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Lenstatin \/ Undisclosed"},{"orgOrder":0,"company":"Guardion Health Sciences","sponsor":"Western University of Health Sciences | Eye Clinic of Austin","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Lumega-Z","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Guardion Health Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Guardion Health Sciences \/ Western University of Health Sciences | Eye Clinic of Austin","highestDevelopmentStatusID":"1","companyTruncated":"Guardion Health Sciences \/ Western University of Health Sciences | Eye Clinic of Austin"},{"orgOrder":0,"company":"Maastricht University Medical Center","sponsor":"Cognis Deutschland GmbH & Co. KG","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"NETHERLANDS","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Lutein","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Maastricht University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maastricht University Medical Center \/ Cognis Deutschland GmbH & Co. KG","highestDevelopmentStatusID":"1","companyTruncated":"Maastricht University Medical Center \/ Cognis Deutschland GmbH & Co. KG"},{"orgOrder":0,"company":"Newtricious R&D BV","sponsor":"Sprim Advanced Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"NETHERLANDS","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Lutein","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Newtricious R&D BV","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Newtricious R&D BV \/ Sprim Advanced Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Newtricious R&D BV \/ Sprim Advanced Life Sciences"},{"orgOrder":0,"company":"Shanghai General Hospital","sponsor":"Innostellar Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LX102-C01","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Shanghai General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai General Hospital \/ Innostellar Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai General Hospital \/ Innostellar Biotherapeutics"},{"orgOrder":0,"company":"Shih Chien Huang","sponsor":"Febico (Far East Bio-Tec Co Ltd)","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Multicomponent Dietary Supplement","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Shih Chien Huang","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shih Chien Huang \/ Febico (Far East Bio-Tec Co Ltd)","highestDevelopmentStatusID":"1","companyTruncated":"Shih Chien Huang \/ Febico (Far East Bio-Tec Co Ltd)"},{"orgOrder":0,"company":"Nu Eyne Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Nu Eyne M02","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Nu Eyne Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nu Eyne Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nu Eyne Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Applied Science & Performance Institute","sponsor":"True Eye Experts - New Tampa | True Eye Experts - Lutz | True Eye Experts - South Tampa","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Nutritears","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Applied Science & Performance Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Science & Performance Institute \/ True Eye Experts - New Tampa | True Eye Experts - Lutz | True Eye Experts - South Tampa","highestDevelopmentStatusID":"1","companyTruncated":"Applied Science & Performance Institute \/ True Eye Experts - New Tampa | True Eye Experts - Lutz | True Eye Experts - South Tampa"},{"orgOrder":0,"company":"Centre Hospitalier Intercommunal Creteil","sponsor":"Laboratoires Thea","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Nutrof","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Centre Hospitalier Intercommunal Creteil","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Hospitalier Intercommunal Creteil \/ Laboratoires Thea","highestDevelopmentStatusID":"1","companyTruncated":"Centre Hospitalier Intercommunal Creteil \/ Laboratoires Thea"},{"orgOrder":0,"company":"Aidan Products LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Ocustem","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Aidan Products LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aidan Products LLC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Aidan Products LLC \/ Undisclosed"},{"orgOrder":0,"company":"Aeon Astron Europe B.V.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"NETHERLANDS","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Ologen Collagen Matrix","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Aeon Astron Europe B.V.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aeon Astron Europe B.V. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Aeon Astron Europe B.V. \/ Undisclosed"},{"orgOrder":0,"company":"LGC Group GB","sponsor":"OliX Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Agreement","leadProduct":"OLX301D","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"LGC Group GB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LGC Group GB \/ OliX Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"LGC Group GB \/ OliX Pharmaceutical"},{"orgOrder":0,"company":"Western University of Health Sciences","sponsor":"Guardion Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Omegaboost","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Western University of Health Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Gummies","sponsorNew":"Western University of Health Sciences \/ Guardion Health Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Western University of Health Sciences \/ Guardion Health Sciences"},{"orgOrder":0,"company":"Institut de la Macula y la Retina","sponsor":"Igen BioLab SLU","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Postbotic","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Institut de la Macula y la Retina","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut de la Macula y la Retina \/ Igen BioLab SLU","highestDevelopmentStatusID":"1","companyTruncated":"Institut de la Macula y la Retina \/ Igen BioLab SLU"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Alpha Bioresearch | Investigaci\u00f3n Estad\u00edstica","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Retilut","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laboratoires Thea \/ Alpha Bioresearch | Investigaci\u00f3n Estad\u00edstica","highestDevelopmentStatusID":"1","companyTruncated":"Laboratoires Thea \/ Alpha Bioresearch | Investigaci\u00f3n Estad\u00edstica"},{"orgOrder":0,"company":"University of Alicante","sponsor":"Pharmactive Biotech Products S.L","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Saffron Extract","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"University of Alicante","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alicante \/ Pharmactive Biotech Products S.L","highestDevelopmentStatusID":"1","companyTruncated":"University of Alicante \/ Pharmactive Biotech Products S.L"},{"orgOrder":0,"company":"University of Alicante","sponsor":"Pharmactive Biotech Products S.L","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Saffron Extract","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"University of Alicante","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alicante \/ Pharmactive Biotech Products S.L","highestDevelopmentStatusID":"1","companyTruncated":"University of Alicante \/ Pharmactive Biotech Products S.L"},{"orgOrder":0,"company":"Turku University Hospital","sponsor":"Aromtech Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FINLAND","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Sea Buckthorn Oil","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Turku University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Turku University Hospital \/ Aromtech Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Turku University Hospital \/ Aromtech Ltd."},{"orgOrder":0,"company":"Selagine","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Collaboration","leadProduct":"SLG-100","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Selagine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Selagine \/ Grifols International","highestDevelopmentStatusID":"1","companyTruncated":"Selagine \/ Grifols International"},{"orgOrder":0,"company":"Aurolab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"SLT","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Aurolab","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurolab \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Aurolab \/ Undisclosed"},{"orgOrder":0,"company":"NTC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Carbohydrate","year":"2017","type":"Inapplicable","leadProduct":"Sodium Hyaluronate Acid","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"NTC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NTC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NTC \/ Undisclosed"},{"orgOrder":0,"company":"Essilor-Polylite Taiwan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Stellest Lenses","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Essilor-Polylite Taiwan","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Essilor-Polylite Taiwan \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Essilor-Polylite Taiwan \/ Undisclosed"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sulfur Hexafluoride","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"Alcon Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Dietary Supplement","year":"2012","type":"Inapplicable","leadProduct":"Systane Lid Wipes","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Alcon Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alcon Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Alcon Inc \/ Undisclosed"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"T7082","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratoires Thea \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Laboratoires Thea \/ Undisclosed"},{"orgOrder":0,"company":"Sight Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Tearcare System","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Sight Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Drops","sponsorNew":"Sight Sciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sight Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Ecolite Group","sponsor":"UCSI University","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Twinkle Eyez","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Ecolite Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ecolite Group \/ UCSI University","highestDevelopmentStatusID":"1","companyTruncated":"Ecolite Group \/ UCSI University"},{"orgOrder":0,"company":"Abilion Medical Systems AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Walther System","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Abilion Medical Systems AB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abilion Medical Systems AB \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Abilion Medical Systems AB \/ Undisclosed"},{"orgOrder":0,"company":"Lundquist Institute for Biomedical Innovation","sponsor":"Allergan | Doheny Image Reading Center","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Lundquist Institute for Biomedical Innovation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lundquist Institute for Biomedical Innovation \/ Allergan | Doheny Image Reading Center","highestDevelopmentStatusID":"1","companyTruncated":"Lundquist Institute for Biomedical Innovation \/ Allergan | Doheny Image Reading Center"},{"orgOrder":0,"company":"Panhandle Eye Group, LLP","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Panhandle Eye Group, LLP","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Panhandle Eye Group, LLP \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Panhandle Eye Group, LLP \/ Undisclosed"},{"orgOrder":0,"company":"Retina Institute of Hawaii","sponsor":"Eyetech Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Macugen","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Retina Institute of Hawaii","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Retina Institute of Hawaii \/ Eyetech Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Retina Institute of Hawaii \/ Eyetech Pharmaceuticals"},{"orgOrder":0,"company":"Kyoto University","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Kyoto University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyoto University \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Kyoto University \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Kyushu University","sponsor":"University of Occupational and Environmental Health | Kurume University | Fukuoka University | Clinical Research Support Center Kyush | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Kyushu University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kyushu University \/ University of Occupational and Environmental Health | Kurume University | Fukuoka University | Clinical Research Support Center Kyush | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Kyushu University \/ University of Occupational and Environmental Health | Kurume University | Fukuoka University | Clinical Research Support Center Kyush | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Vision Research Foundation","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Vision Research Foundation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vision Research Foundation \/ Genentech","highestDevelopmentStatusID":"1","companyTruncated":"Vision Research Foundation \/ Genentech"},{"orgOrder":0,"company":"PolyPhotonix Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"PolyPhotonix Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PolyPhotonix Medical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"PolyPhotonix Medical \/ Undisclosed"},{"orgOrder":0,"company":"Oraya Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Ranibizumab","moa":"Vascular endothelial growth factor A","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Oraya Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oraya Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Oraya Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rothschild Foundation Hospital","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Rothschild Foundation Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rothschild Foundation Hospital \/ Bayer AG","highestDevelopmentStatusID":"1","companyTruncated":"Rothschild Foundation Hospital \/ Bayer AG"},{"orgOrder":0,"company":"Berner Augenklinik","sponsor":"Medignition","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Berner Augenklinik","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Berner Augenklinik \/ medignition","highestDevelopmentStatusID":"1","companyTruncated":"Berner Augenklinik \/ medignition"},{"orgOrder":0,"company":"Vitreous Retina Macula Consultants of New York","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Vitreous Retina Macula Consultants of New York","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vitreous Retina Macula Consultants of New York \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Vitreous Retina Macula Consultants of New York \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Manhattan Eye, Ear & Throat Hospital","sponsor":"Northwell Health","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Manhattan Eye, Ear & Throat Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Manhattan Eye, Ear & Throat Hospital \/ Northwell Health","highestDevelopmentStatusID":"1","companyTruncated":"Manhattan Eye, Ear & Throat Hospital \/ Northwell Health"},{"orgOrder":0,"company":"Duke University","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duke University \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"1","companyTruncated":"Duke University \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"MidAtlantic Retina","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Aflibercept","moa":"Vascular endothelial growth factor A | Placenta growth factor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"MidAtlantic Retina","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MidAtlantic Retina \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"MidAtlantic Retina \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Novelty Nobility","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GC Biopharma \/ Novelty Nobility","highestDevelopmentStatusID":"1","companyTruncated":"GC Biopharma \/ Novelty Nobility"},{"orgOrder":0,"company":"AronPharma Sp. z o. o.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"POLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"AronPharma Sp. z o. o.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AronPharma Sp. z o. o. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AronPharma Sp. z o. o. \/ Undisclosed"},{"orgOrder":0,"company":"Re-Vana Therapeutics","sponsor":"Visionary Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Re-Vana Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Implant","sponsorNew":"Re-Vana Therapeutics \/ Visionary Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Re-Vana Therapeutics \/ Visionary Ventures"},{"orgOrder":0,"company":"Ikarovec","sponsor":"Rentschler Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Ikarovec","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ikarovec \/ Rentschler Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Ikarovec \/ Rentschler Biopharma"},{"orgOrder":0,"company":"Ikarovec","sponsor":"UKi2S","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Ikarovec","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ikarovec \/ UKi2S","highestDevelopmentStatusID":"1","companyTruncated":"Ikarovec \/ UKi2S"},{"orgOrder":0,"company":"Pharmathen SA","sponsor":"Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GREECE","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Pharmathen SA","amount2":1.8999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":1.8999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Pharmathen SA \/ Partners Group","highestDevelopmentStatusID":"1","companyTruncated":"Pharmathen SA \/ Partners Group"},{"orgOrder":0,"company":"Istanbul Medipol University Hospital","sponsor":"Varol TUNALI | Liv Hospital (Ulus)","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TURKEY","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Istanbul Medipol University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Istanbul Medipol University Hospital \/ Varol TUNALI | Liv Hospital (Ulus)","highestDevelopmentStatusID":"1","companyTruncated":"Istanbul Medipol University Hospital \/ Varol TUNALI | Liv Hospital (Ulus)"},{"orgOrder":0,"company":"Lumenis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Lumenis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lumenis \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Lumenis \/ Undisclosed"},{"orgOrder":0,"company":"ScienceBased Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"ScienceBased Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ScienceBased Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"ScienceBased Health \/ Undisclosed"},{"orgOrder":0,"company":"GelMEDIX","sponsor":"HTL Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Hyaluronic Acid","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"GelMEDIX","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"GelMEDIX \/ HTL Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"GelMEDIX \/ HTL Biotechnology"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Melatonin receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Palatin Technologies","amount2":0.33000000000000002,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0.33000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Palatin Technologies \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Palatin Technologies \/ Boehringer Ingelheim GmbH"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Details :
The collaboration strengthens Boehringer’s innovative and diversified pipeline in retinal conditions and its underlying commitment to vision preservation and protection.
Details :
Eye Empower is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Dry Eye Syndromes.
Details :
Multicomponent Dietary Supplement is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Dry Eye Syndromes.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
December 17, 2024
Lead Product(s) :
Multicomponent Dietary Supplement
Details :
Under the agreement terms, GC and Novelty will partner to jointly R&D antibody-based protein therapeutics for geographic atrophy, supporting all stages of the drug development lifecycle.
Details :
Twinkle Eyez is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Dry Eye Syndromes.
Reset All
